Geneformatics And Incyte Genomics Sign Collaborative Agreement To Annotate Functions Of Protein Sequences

24-Apr-2002

San Diego, CA and Palo Alto, CA - April 23, 2002 - GeneFormatics, Inc. and Incyte Genomics, Inc., today announced that they have entered into a collaborative research agreement. Under the terms of the agreement, GeneFormatics will use its proprietary and integrated structural proteomics technologies to identify the function and associated structure of proprietary full-length human protein sequences provided by Incyte. Information generated may be utilized by Incyte to enable its genomic patent filings. Financial terms were not disclosed. "We are pleased to have the opportunity to work with Incyte to characterize a large number of potential therapeutic and target proteins for drug discovery," said John Chiplin, Ph.D., President and Chief Executive Officer of GeneFormatics. "Our integrated technologies will elucidate function and structure information from Incyte's protein sequences, allowing Incyte to expand its already impressive intellectual property portfolio with greater grasp of genomic functional value. In addition, industry collaborations such as the Incyte collaboration validate the GeneFormatics intellectual property and licensing strategies." "GeneFormatics' integrated approach to analyzing protein sequences is on the cutting edge of structural proteomics research," said Robert Stein, M.D., Ph.D., President and Chief Scientific Officer at Incyte. "This collaboration should further strengthen our intellectual property portfolio and aid our therapeutic discovery and development efforts by providing greater functional understanding of genomic protein sequences."

https://www.bionity.com/en/news/10331/geneformatics-and-incyte-genomics-sign-collaborative-agreement-to-annotate-functions-of-protein-sequences.html